Global Information
회사소개 | 문의 | 비교리스트

첨단 약물전달 시장 : 제품 유형(약물용출렌즈, 마이크로니들 패치, 하이드로겔 약물전달, 나노캐리어), 최종사용자별(병원, 전문 클리닉, 기타) - 세계 기회 분석 및 산업 예측(2021-2030년)

Advanced Drug Delivery Market by Product Type (Drug Eluting Lens, Microneedle Patch, Hydrogel Drug Delivery and Nano Carrier) and End User (Hospitals, Specialized Clinics and Others): Global Opportunity Analysis and Industry Forecast, 2021-2030

리서치사 Allied Market Research
발행일 2021년 12월 상품코드 1059561
페이지 정보 영문 190 Pages 배송안내 2-3일 (영업일 기준)
가격
US $ 4,125 ₩ 5,256,000 Excel (Data Pack) help
DRM(디지털 저작권 관리 시스템) 장착 Excel 파일로, 1명만 이용할 수 있는 라이선스입니다. 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 Excel파일 라이선스 소유자로 한정됩니다.
US $ 6,168 ₩ 7,859,000 PDF (Single User License + Covid impact) help
DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste 가 되지 않으며, 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 PDF 라이선스 소유자로 한정됩니다.
US $ 6,929 ₩ 8,828,000 PDF (5-user License) help
DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 5명까지 이용할 수 있는 라이선스입니다. 인쇄는 5회까지 가능하며 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,663 ₩ 13,586,000 PDF (Enterprise User License) help
동일 기업 내의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



첨단 약물전달 시장 : 제품 유형(약물용출렌즈, 마이크로니들 패치, 하이드로겔 약물전달, 나노캐리어), 최종사용자별(병원, 전문 클리닉, 기타) - 세계 기회 분석 및 산업 예측(2021-2030년) Advanced Drug Delivery Market by Product Type (Drug Eluting Lens, Microneedle Patch, Hydrogel Drug Delivery and Nano Carrier) and End User (Hospitals, Specialized Clinics and Others): Global Opportunity Analysis and Industry Forecast, 2021-2030
발행일 : 2021년 12월 페이지 정보 : 영문 190 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 첨단 약물전달 시장 규모는 2020년 440억 2,959만 달러에서 예측 기간 중 16.0%의 CAGR로 추이하며, 2030년에는 1,951억 3,245만 달러 규모로 성장할 것으로 예측됩니다.

첨단 약물전달 시장의 성장은 만성질환의 유병률 상승이 주요 요인입니다. 또한 신약 및 생물제제의 개발로 연결되는 R&D 활동과 진보도 시장 성장을 촉진하고 있습니다.

세계의 첨단 약물전달 시장을 조사했으며, 시장의 정의와 개요, 시장 영향요인 분석, 특허 동향, 임상시험 분석, 시장 규모의 추이·예측, 제품 유형·최종사용자·지역/주요 국가 등 각종 부문별 내역, 경쟁 환경, 주요 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 서론

제2장 개요

제3장 시장의 개요

  • 시장의 정의와 범위
  • 주요 조사 결과
  • Porter의 산업 분석
  • 주요 기업의 포지셔닝
  • 시장 역학
    • 촉진요인
    • 억제요인
    • 시장 기회
  • 영향 분석
  • COVID-19 : 영향 분석
  • 특허 분석
  • 임상시험 분석

제4장 첨단 약물전달 시장 : 제품 유형별

  • 개요
  • 약제용출렌즈
  • 마이크로니들 패치
  • 하이드로겔 약물전달
  • 나노캐리어
    • 주요 시장 동향·성장요인·기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별

제5장 첨단 약물전달 시장 : 최종사용자별

  • 개요
  • 병원
  • 전문 클리닉
  • 기타
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별

제6장 첨단 약물전달 시장 : 지역별

  • 개요
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카·중동·아프리카
    • 주요 시장 동향·성장요인·기회
    • 첨단 약물전달 시장 : 제품 유형별
    • 첨단 약물전달 시장 : 최종사용자별
    • 첨단 약물전달 시장 : 국가별

제7장 기업 개요

  • ALNYLAM PHARMACEUTICALS, INC.
  • ALTARIS CAPITAL PARTNERS, LLC.(KINDEVA DRUG DELIVERY)
  • BAUSCH HEALTH COMPANIES INC.(BAUSCH & LOMB)
  • BIOGEN LIMITED
  • ENDO INTERNATIONAL PLC.
  • JOHNSON & JOHNSON(JOHNSON & JOHNSON VISION)
  • MICROPOINT TECHNOLOGIES PTE LTD.
  • NOVO NORDISK
  • OCULAR THERAPEUTIX, INC.
  • TAKEDA PHARMACEUTICAL COMPANY LIMITED
KSA 22.03.07

LIST OF TABLES

  • TABLE 01.ADVANCED DRUG DELIVERY MARKET, BY CLINICAL TRIALS
  • TABLE 02.ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 03.ADVANCED DRUG DELIVERY MARKET FOR MICRONEEDLE PATCH, BY REGION, 2020-2030 ($MILLION)
  • TABLE 04.ADVANCED DRUG DELIVERY MARKET FOR HYDROGEL DRUG DELIVERY MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 05.ADVANCED DRUG DELIVERY MARKET FOR NANO CARRIER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 06.ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 07.ADVANCED DRUG DELIVERY MARKET FOR HOSPITALS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 08.ADVANCED DRUG DELIVERY MARKET FOR SPECIALIZED CLINICS, BY REGION, 2020-2030($MILLION)
  • TABLE 09.ADVANCED DRUG DELIVERY MARKET FOR OTHERS, BY REGION, 2020-2030($MILLION)
  • TABLE 10.ADVANCED DRUG DELIVERY MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 11.NORTH AMERICA ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 12.NORTH AMERICA ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 13.NORTH AMERICA ADVANCED DRUG DELIVERY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 14.U.S. ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 15.U.S. ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 16.CANADA ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 17.CANADA ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 18.MEXICO ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 19.MEXICO ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 20.EUROPE ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 21.EUROPE ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 22.EUROPE ADVANCED DRUG DELIVERY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 23.GERMANY ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 24.GERMANY ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 25.FRANCE ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 26.FRANCE ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 27.UK ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 28.UK ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 29.ITALY ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 30.ITALY ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 31.SPAIN ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 32.SPAIN ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 33.REST OF EUROPE ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 34.REST OF EUROPE ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 35.ASIA-PACIFIC ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 36.ASIA-PACIFIC ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 37.ASIA-PACIFIC ADVANCED DRUG DELIVERY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 38.JAPAN ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 39.JAPAN ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 40.CHINA ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 41.CHINA ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 42.AUSTRALIA ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 43.AUSTRALIA ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 44.INDIA ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 45.INDIA ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 46.SOUTH KOREA ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 47.SOUTH KOREA ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 48.REST OF ASIA-PACIFIC ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 49.REST OF ASIA-PACIFIC ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 50.LAMEA ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 51.LAMEA ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 52.LAMEA ADVANCED DRUG DELIVERY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 53.BRAZIL ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 54.BRAZIL ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 55.SAUDI ARABIA ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 56.SAUDI ARABIA ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 57.SOUTH AFRICA ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 58.SOUTH AFRICA ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 59.REST OF LAMEA ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 60.REST OF LAMEA ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 61.ALNYLAM: COMPANY SNAPSHOT
  • TABLE 62.ALNYLAM: OPERATING BUSINESS SEGMENTS
  • TABLE 63.ALNYLAM: PRODUCT PORTFOLIO
  • TABLE 64.ALNYLAM: KEY DEVELOPMENTS
  • TABLE 65.ALTARIS: COMPANY SNAPSHOT
  • TABLE 66.ALTARIS: OPERATING SEGMENTS
  • TABLE 67.ALTARIS HEALTHCARE: PRODUCT PORTFOLIO
  • TABLE 68.BAUSCH: COMPANY SNAPSHOT
  • TABLE 69.BAUSCH: OPERATING SEGMENTS
  • TABLE 70.BAUSCH: PRODUCT PORTFOLIO
  • TABLE 71.BIOGEN: COMPANY SNAPSHOT
  • TABLE 72.BIOGEN: OPERATING SEGMENTS
  • TABLE 73.BIOGEN: PRODUCT PORTFOLIO
  • TABLE 74.BIOGEN: KEY DEVELOPMENTS
  • TABLE 75.ENDO: COMPANY SNAPSHOT
  • TABLE 76.ENDO: OPERATING BUSINESS SEGMENTS
  • TABLE 77.ENDO: PRODUCT PORTFOLIO
  • TABLE 78.JOHNSON: COMPANY SNAPSHOT
  • TABLE 79.JOHNSON: PRODUCT SEGMENTS
  • TABLE 80.JOHNSON: PRODUCT PORTFOLIO
  • TABLE 81.JOHNSON: KEY DEVELOPMENTS
  • TABLE 82.MICROPOINT: SNAPSHOT
  • TABLE 83.MICROPOINT: OPERATING SEGMENT
  • TABLE 84.MICROPOINT: PRODUCT PORTFOLIO
  • TABLE 85.NOVO NORDISK: COMPANY SNAPSHOT
  • TABLE 86.NOVO NORDISK: OPERATING SEGMENTS
  • TABLE 87.NOVO NORDISK: PRODUCT PORTFOLIO
  • TABLE 88.BIOGEN: KEY DEVELOPMENTS
  • TABLE 89.OCULAR THERAPEUTIX: COMPANY SNAPSHOT
  • TABLE 90.OCULAR THERAPEUTIX: OPERATING SEGMENTS
  • TABLE 91.OCULAR THERAPEUTIX: PRODUCT PORTFOLIO
  • TABLE 92.OCULAR THERAPEUTIX: KEY DEVELOPMENTS

LIST OF FIGURES

  • FIGURE 01.GLOBAL ADVANCED DRUG DELIVERY MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2021
  • FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2021
  • FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2019-2021
  • FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 08.MODERATE THREAT OF SUBSTITUTES
  • FIGURE 09.HIGH THREAT OF NEW ENTRANTS
  • FIGURE 10.HIGH INTENSITY OF RIVALRY
  • FIGURE 11.TOP PLAYER POSITIONING, 2020
  • FIGURE 12.IMPACT ANALYSIS
  • FIGURE 13.PATENTS REGISTERED/APPROVED IN THE WORLD, 2019-2021
  • FIGURE 14.PATENTS ANALYSIS, BY YEAR, 2019-2021
  • FIGURE 15.COMPARATIVE ANALYSIS OF ADVANCED DRUG DELIVERY MARKET FOR MICRONEEDLE PATCH, BY COUNTRY, 2020-2030 (%)
  • FIGURE 16.COMPARATIVE ANALYSIS OF ADVANCED DRUG DELIVERY MARKET FOR HYDROGEL DRUG DELIVERY, BY COUNTRY, 2020-2030 (%)
  • FIGURE 17.COMPARATIVE ANALYSIS OF ADVANCED DRUG DELIVERY MARKET FOR NANO CARRIER, BY COUNTRY, 2020-2030 (%)
  • FIGURE 18.COMPARATIVE ANALYSIS OF ADVANCED DRUG DELIVERY MARKET FOR HOSPITALS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 19.COMPARATIVE ANALYSIS OF ADVANCED DRUG DELIVERY MARKET FOR SPECIALIZED CLINICS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 20.COMPARATIVE ANALYSIS OF ADVANCED DRUG DELIVERY MARKET FOR OTHERS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 21.ALNYLAM: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 22.BAUSCH: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 23.BAUSCH: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 24.BAUSCH: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 25.BIOGEN: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 26.ENDO: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 27.ENDO: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 28.JOHNSON: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 29.JOHNSON: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 30.JOHNSON: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 31.NET SALES, 2018-2020 ($MILLION)
  • FIGURE 32.NOVO NORDISK: REVENUE SHARE BY SEGMENT, 2020 (%)

The global advanced drug delivery market was valued at $44,029.59 million in 2020, and is estimated to reach $1,95,132.45 million by 2030, growing at a CAGR of 16.0% from 2021 to 2030. Advanced drug delivery is an improved method for delivering the drug molecule to the targeted site in a more controlled manner. Advance drug delivery systems are based on novel drug delivery techniques and utilize the most advanced technologies. They are intended to administer the medicine in a regulated or modulated manner within the tissue or cells, with the goal of providing safe and effective therapy.

The advanced drug delivery system comprises oral, parenteral, pulmonary, transmucosal, transdermal, carrier based systems like nanoparticles, nanospheres, nanocapsules, nanoemulsions, and nano-sized vesicular carriers, such as liposomes, niosomes, dendrimers, and polymeric or lipid-based carriers and other drug delivery systems. These advanced drug delivery technologies have the potential to overcome the limitations of the already existing drugs. Various factors, such as pharmacodynamics, drug toxicity, immunogenicity, bio compatibility, pharmacokinetics, and drug efficacy, are considered while developing advanced drug delivery systems.

The primary goal of adopting advanced drug delivery (ADD) is not only to deliver a biologically active molecule in a regulated way (time, period and releasing rate), but also to keep drug levels in the body within the therapeutic window. Furthermore, the drug can be directed toward a specific organ or tissue (targeted drug delivery).

They assist in the delivery of medication levels in the body by minimizing toxicity and effectively delivering the drug at the intended location of action. The key benefit of ADD is its flexibility and potential to increase drug bioavailability. Drug therapeutic efficacy and safety profiles can be enhanced by more accurate spatial and temporal placement in the body, resulting in lower dosage frequency. These techniques are being developed to improve the efficacy ratio of currently available medications. The development of advanced drug delivery systems is based on the delivery of drugs at a controlled pace, as well as slow and targeted distribution for onsite drug release and absorption.

The growth of advanced drug delivery market is majorly driven by rise in prevalence of chronic diseases. Chronic diseases are described generally as problems that persist a year or longer and need continuous medical treatment, that limit everyday activities, or both.

According to the Center of Disease Control and Prevention (CDC) in 2020, every year, more than 868,000 Americans succumb to heart disease, stroke, or other cardiovascular disorders, accounting for one-third of all deaths in the U.S. 6 out of 10 Americans have at least one chronic condition, and 4 out of 10 have two or more heart, stroke, cancer, or diabetes. These and other chronic diseases are the leading causes of death and disability in the U.S. and they are also a leading driver of healthcare costs. These diseases also take an economic toll, costing $214 billion a year to the health care system and causing $138 billion in lost productivity from premature death alone. They are also major contributors to the country's $3.8 trillion in yearly health-care expenses. Thus, rise in chronic diseases leads to the surge in demand of advanced drug delivery for safe and effective therapy.

In addition, the market is driven by advancements as well as R&D activities in understanding of human biology and diseases leading to the development of new drugs and biologics. For instance, in December 2019, researchers at the Massachusetts Institute of Technology (MIT) have developed a microneedle platform that uses quantum dots (QD), which are fluorescent microparticles that can deliver vaccines while also invisibly encoding vaccination history in the skin. The quantum dots are made up of nanocrystals that emit near-infrared light that may be detected by a smartphone with a specific sensor. Thus, such developments significantly boost the advanced drug delivery market.

However, rise in number of drug recalls and drug failures of advanced drug delivery, challenges in nanomedicine based drug delivery are expected to hamper the market growth. For instance, according to the USFDA's Center for Drug Evaluation and Research (CDER) in 2020 about 53 new molecular entities (NMEs) were approved. Thus, rise in such drug approvals and innovations further drives the market for designing various advanced drug delivery systems. Furthermore, increase in R&D spending and surge in healthcare expenditure worldwide, specifically in the developing economies leads to an increased demand for advanced drug delivery products for better efficacy and thus, is a great opportunity for the key players of the market for investment.

The global advanced drug delivery market is segmented on the basis of product type, end user, and region. On the basis of product type, the market is segregated into drug eluting lens, microneedle patch, hydrogel drug delivery and nano carrier. By end user, it is fragmented into hospitals, specialized clinics and others. On the basis of region, the market is analyzed across North America, Europe, Asia-Pacific and LAMEA.

The major players profiled in the report are Alnylam Pharmaceuticals Inc., Altaris Capital Partners Llc. (Kindeva Drug Delivery), Bausch Health Companies Inc., (Bausch & Lomb), Biogen Limited, Endo International Plc., Johnson & Johnson (Johnson & Johnson Vision), Micropoint Technologies, Novo Nordisk A/S, Ocular Therapeutix Inc. and Takeda Pharmaceutical Company Limited.

KEY BENEFITS FOR STAKEHOLDERS

  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the global advanced drug delivery market to identify the prevailing opportunities.
  • This study presents the competitive landscape of the global market to predict the competitive environment across geographies.
  • Comprehensive analysis of factors that drive and restrict the market growth is provided.
  • Region- & country-wise analysis is provided to understand the market trends and dynamics.

KEY MARKET SEGMENTS

By Product Type

  • Drug eluting lens
  • Microneedle patch
  • Hydrogel drug delivery
  • Nano carrier

By End User

  • Hospitals
  • Specialized clinics
  • Others

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

KEY MARKET PLAYERS

  • Alnylam Pharmaceuticals Inc.
  • Altaris Capital Partners Llc. (Kindeva Drug Delivery)
  • Bausch Health Companies Inc., (Bausch & Lomb)
  • Biogen Limited
  • Endo International Plc.
  • Johnson & Johnson (Johnson & Johnson Vision)
  • Micropoint Technologies
  • Novo Nordisk A/S
  • Ocular Therapeutix Inc.
  • Takeda Pharmaceutical Company Limited

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
    • 1.3.1.List of key players profile in the report
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
    • 3.2.2.Top winning strategies
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning, 2020
  • 3.5.Market dynamics
    • 3.5.1.Drivers
      • 3.5.1.1.Rise in prevalence of chronic disorders that require the use of drug delivery systems
      • 3.5.1.2.Surge in healthcare expenditure worldwide
      • 3.5.1.3.Technological advancements and developments made by key players in drug delivery system market
    • 3.5.2.Restraint
      • 3.5.2.1.Rise in number of drug recalls and drug failures
    • 3.5.3.Opportunity
      • 3.5.3.1.Lucrative opportunities in emerging markets
  • 3.6.Impact analysis
  • 3.7.Impact analysis of COVID-19 on the advanced drug delivery market
  • 3.8.Patent analysis, 2019-2021
    • 3.8.1.Patent analysis, by world
    • 3.8.2.Patent analysis, by year
  • 3.9.Clinical trials analysis, 2019-2021

CHAPTER 4:ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Drug eluting lens
    • 4.2.1.Key market trends, growth factors, and opportunities
  • 4.3.Microneedle patch
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast, by region
    • 4.3.3.Market analysis, by country
  • 4.4.Hydrogel drug delivery
    • 4.4.1.Key market trends, growth factors, and opportunities
    • 4.4.2.Market size and forecast, by region
    • 4.4.3.Market analysis, by country
  • 4.5.Nano carrier
    • 4.5.1.Key market trends, growth factors, and opportunities
    • 4.5.2.Market size and forecast, by region
    • 4.5.3.Market analysis, by country

CHAPTER 5:ADVANCED DRUG DELIVERY MARKET, BY END USER

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Hospitals
    • 5.2.1.Market size and forecast, by region
    • 5.2.2.Market analysis, by country
  • 5.3.Specialized clinics
    • 5.3.1.Market size and forecast, by region
    • 5.3.2.Market analysis, by country
  • 5.4.Others
    • 5.4.1.Market size and forecast, by region
    • 5.4.2.Market analysis, by country

CHAPTER 6:ADVANCED DRUG DELIVERY MARKET, BY REGION

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.North America
    • 6.2.1.Key market trends, growth factors, and opportunities
    • 6.2.2.North America advanced drug delivery market, by product type
    • 6.2.3.North America advanced drug delivery market, by end user
    • 6.2.4.Market size and forecast, by country
      • 6.2.4.1.U.S.
      • 6.2.4.1.1.U.S. advanced drug delivery market, by product type
      • 6.2.4.1.2.U.S. advanced drug delivery market, by end user
      • 6.2.4.2.Canada
      • 6.2.4.2.1.Canada advanced drug delivery market, by product type
      • 6.2.4.2.2.Canada advanced drug delivery market, by end user
      • 6.2.4.3.Mexico
      • 6.2.4.3.1.Mexico advanced drug delivery market, by product type
      • 6.2.4.3.2.Mexico advanced drug delivery market, by end user
  • 6.3.Europe
    • 6.3.1.Key market trends, growth factors, and opportunities
    • 6.3.2.Europe advanced drug delivery market, by product type
    • 6.3.3.Europe advanced drug delivery market, by end user
    • 6.3.4.Market size and forecast, by country
      • 6.3.4.1.Germany
      • 6.3.4.1.1.Germany advanced drug delivery market, by product type
      • 6.3.4.1.2.Germany advanced drug delivery market, by end user
      • 6.3.4.2.France
      • 6.3.4.2.1.France advanced drug delivery market, by product type
      • 6.3.4.2.2.France advanced drug delivery market, by end user
      • 6.3.4.3.UK
      • 6.3.4.3.1.UK advanced drug delivery market, by product type
      • 6.3.4.3.2.UK advanced drug delivery market, by end user
      • 6.3.4.4.Italy
      • 6.3.4.4.1.Italy advanced drug delivery market, by product type
      • 6.3.4.4.2.Italy advanced drug delivery market, by end user
      • 6.3.4.5.Spain
      • 6.3.4.5.1.Spain advanced drug delivery market, by product type
      • 6.3.4.5.2.Spain advanced drug delivery market, by end user
      • 6.3.4.6.Rest of Europe
      • 6.3.4.6.1.Rest of Europe advanced drug delivery market, by product type
      • 6.3.4.6.2.Rest of Europe advanced drug delivery market, by end user
  • 6.4.Asia-Pacific
    • 6.4.1.Key market trends, growth factors, and opportunities
    • 6.4.2.Asia-Pacific advanced drug delivery market, by product type
    • 6.4.3.Asia-Pacific advanced drug delivery market, by end user
    • 6.4.4.Market size and forecast, by country
      • 6.4.4.1.Japan
      • 6.4.4.1.1.Japan advanced drug delivery market, by product type
      • 6.4.4.1.2.Japan advanced drug delivery market, by end user
      • 6.4.4.2.China
      • 6.4.4.2.1.China advanced drug delivery market, by product type
      • 6.4.4.2.2.China advanced drug delivery market, by end user
      • 6.4.4.3.Australia
      • 6.4.4.3.1.Australia advanced drug delivery market, by product type
      • 6.4.4.3.2.Australia advanced drug delivery market, by end user
      • 6.4.4.4.India
      • 6.4.4.4.1.India advanced drug delivery market, by product type
      • 6.4.4.4.2.India advanced drug delivery market, by end user
      • 6.4.4.5.South Korea
      • 6.4.4.5.1.South Korea advanced drug delivery market, by product type
      • 6.4.4.5.2.South Korea advanced drug delivery market, by end user
      • 6.4.4.6.Rest of Asia-Pacific
      • 6.4.4.6.1.Rest of Asia-Pacific advanced drug delivery market, by product type
      • 6.4.4.6.2.Rest of Asia-Pacific advanced drug delivery market, by end user
  • 6.5.LAMEA
    • 6.5.1.Key market trends, growth factors, and opportunities
    • 6.5.2.LAMEA advanced drug delivery market, by product type
    • 6.5.3.LAMEA advanced drug delivery market, by end user
    • 6.5.4.LAMEA advanced drug delivery market, by country
      • 6.5.4.1.Brazil
      • 6.5.4.1.1.Brazil advanced drug delivery market, by product type
      • 6.5.4.1.2.Brazil advanced drug delivery market, by end user
      • 6.5.4.2.Saudi Arabia
      • 6.5.4.2.1.Saudi Arabia advanced drug delivery market, by product type
      • 6.5.4.2.2.Saudi Arabia advanced drug delivery market, by end user
      • 6.5.4.3.South Africa
      • 6.5.4.3.1.South Africa advanced drug delivery market, by product type
      • 6.5.4.3.2.South Africa advanced drug delivery market, by end user
      • 6.5.4.4.Rest of LAMEA
      • 6.5.4.4.1.Rest of LAMEA advanced drug delivery market, by product type
      • 6.5.4.4.2.Rest of LAMEA advanced drug delivery market, by end user

CHAPTER 7:COMPANY PROFILES

  • 7.1.ALNYLAM PHARMACEUTICALS, INC.
    • 7.1.1.Company overview
    • 7.1.2.Company snapshot
    • 7.1.3.Operating business segments
    • 7.1.4.Product portfolio
    • 7.1.5.Business performance
    • 7.1.6.Key strategic moves and developments
  • 7.2.ALTARIS CAPITAL PARTNERS, LLC. (KINDEVA DRUG DELIVERY)
    • 7.2.1.Company overview
    • 7.2.2.Company snapshot
    • 7.2.3.Operating business segments
    • 7.2.4.Product portfolio
  • 7.3.BAUSCH HEALTH COMPANIES INC. (BAUSCH & LOMB)
    • 7.3.1.Company overview
    • 7.3.2.Company snapshot
    • 7.3.3.Operating business segments
    • 7.3.4.Product portfolio
    • 7.3.5.Business performance
  • 7.4.BIOGEN LIMITED
    • 7.4.1.Company overview
    • 7.4.2.Company snapshot
    • 7.4.3.Operating business segments
    • 7.4.4.Product portfolio
    • 7.4.5.Business performance
    • 7.4.6.Key strategic moves and developments
  • 7.5.ENDO INTERNATIONAL PLC.
    • 7.5.1.Company overview
    • 7.5.2.Company snapshot
    • 7.5.3.Operating business segments
    • 7.5.4.Product portfolio
    • 7.5.5.Business performance
  • 7.6.JOHNSON & JOHNSON (JOHNSON & JOHNSON VISION)
    • 7.6.1.Company overview
    • 7.6.2.Company snapshot
    • 7.6.3.Operating business segments
    • 7.6.4.Product portfolio
    • 7.6.5.Business performance
    • 7.6.6.Key strategic moves and developments
  • 7.7.MICROPOINT TECHNOLOGIES PTE LTD.
    • 7.7.1.Company overview
    • 7.7.2.Company snapshot
    • 7.7.3.Operating business segments
    • 7.7.4.Product portfolio
  • 7.8.NOVO NORDISK
    • 7.8.1.Company overview
    • 7.8.2.Company snapshot
    • 7.8.3.Operating business segments
    • 7.8.4.Product portfolio
    • 7.8.5.Business performance
    • 7.8.6.Key strategic moves and developments
  • 7.9.OCULAR THERAPEUTIX, INC.
    • 7.9.1.Company overview
    • 7.9.2.Company snapshot
    • 7.9.3.Operating business segments
    • 7.9.4.Product portfolio
    • 7.9.5.Key strategic moves and developments
  • 7.10.TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • 7.10.1.Company overview
    • 7.10.2.Operating business segments
    • 7.10.3.Product portfolio
    • 7.10.4.Business performance
Back to Top
전화 문의
F A Q